eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Head & Neck Surgery

Malignant Tumors of the Larynx: Treatment

Author: Jonas T Johnson, MD, FACS, Chairman, Department of Otolaryngology, The Eugene N Myers, MD, Professor and Chairman of Otolaryngology, Professor, Department of Radiation Oncology, University of Pittsburgh School of Medicine; Professor, Department of Oral Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Coauthor(s): Apostolos Christopoulos, MD, MSc, FRCSC, Fellow in Head and Neck Oncologic Surgery, Department of Otolaryngology, University of Pittsburgh; Emiro E Caicedo-Granados, MD, Fellow in Head and Neck Oncology/Anterior Endoscopic Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh
Contributor Information and Disclosures

Updated: Jan 7, 2009

Treatment

Medical Therapy

Treatment of patients with laryngeal carcinoma is complex because of the crucial functions of this anatomic area. If possible, the goal of treatment is to remove the tumor and prevent recurrence while maintaining laryngeal function.

To discuss the treatment options for laryngeal cancer, one must differentiate early (I-II) and advanced (III-IV) stage disease. Subsite location of the primary tumor, glottic, supraglottic or subglottic is also an important consideration when selecting therapy. Early-stage laryngeal carcinomas (stage I-II) are ideally treated with voice-saving surgery. Advanced-stage laryngeal carcinomas (stage III) are usually treated with concurrent chemo-radiation therapy for organ preservation. On the other hand, advanced laryngeal cancer (stage IV) is usually treated with total laryngectomy, reconstruction, and adjuvant postoperative chemoradiation therapy.

For carcinoma in situ or early-stage invasive glottic or supraglottic cancer, endoscopic surgical removal or radiation therapy are both equally effective with similar functional outcomes. The treatment modality depends on the patient’s wishes and compliance and the surgeon's and the institution's preferences and experience. A more complete discussion of surgical options is presented in Surgical Therapy.

Remarkable progress has been made in the past 20 years in the management of laryngeal cancer. Where total laryngectomy held a central role in the treatment of advanced laryngeal tumors, organ preservation strategies using chemotherapy and radiation therapy protocols have now become the standard of care. Landmark studies such as The Veteran Affairs Laryngeal Cancer Study Group in 1991 and the RTOG 91-11 intergroup trial helped establish the basis of laryngeal preservation therapies using chemotherapy (cisplatinum and fluorouracil) and radiation therapy protocols.2  Support for chemotherapy as part of a multimodality approach has been strengthened by many subsequent clinical trials with a slight benefit of concurrent chemoradiation protocols.

Current recommendations of the NCCN Practice Guidelines in Oncology for achieving laryngeal preservation in cases of locally advanced laryngeal cancer are concurrent radiation therapy and cisplatin 100mg/m2 on days 1, 22, and 43.3 Radiation therapy alone can be considered for patients who are medically unfit to undergo chemotherapy. Good evidence exists that radiation efficacy is improved with accelerated and hyperfractionated treatment schemes. Concurrent chemoradiotherapy protocols are associated with significant acute and late toxicities. Some patients remain with dysfunctional swallowing and life-threatening aspiration episodes that require salvage laryngectomy.

Although the pendulum has swung toward larynx preservation protocols, laryngectomy is the best initial therapeutic option in certain situations. Primary surgical treatment should be considered in patients with high volume disease, patients with T4a tumors, or patients with anticipated poor functional outcome (eg. poor voice, intractable aspiration). 

Significant early and late toxicities associated with concurrent chemoradiation protocols led to recent interest in targeted therapies such as monoclonal antibodies (eg, cetuximab). Cetuximab is presently used in many organ preservation protocols for laryngeal cancer following a landmark multicenter trial. Many other targeted therapies are under investigation.

In summary, therapy is predicated on histology type, grade, tumor stage, and overall health of the patient. Treatment must be individualized to consider each patient and his or her social circumstances.

Surgical Therapy

Although laryngeal preservation strategies using chemoradiation have taken a central role in the treatment of advanced laryngeal cancer, late toxicities have led us to rethink the paradigm of laryngeal cancer treatment. The refinement of laryngeal surgeries and the sophistication of endolaryngeal laser techniques offer a wide array of laryngeal preservation options that should be carefully considered by the multidisciplinary team. As described in the previous section, total laryngectomy must be considered in cases of bulky or advanced disease, clear cartilage invasion, and failures of larynx-sparing strategies. The description of the surgical technique of partial and total laryngectomy is beyond the scope of this article.

Transoral laser microsurgery

  • Transoral laser microsurgery is ideal for the treatment of early-intermediate glottic and supraglottic cancer.
  • It is performed under suspension micro-laryngoscopy with a CO2 laser.
  • It was popularized and legitimized by Steiner and Ambrosch.
  • The tumor is transected and removed piecemeal (which allows for precise tumor removal by margin visualization).
  • The Tumor must be well exposed through the laryngoscope.
  • Adequate instrumentation and surgeon's experience are paramount.
  • This treatment has the same indications and contraindications as open partial laryngectomies. A functional cricoarytenoid unit must be preserved.
  • Survival and laryngeal preservation is comparable to other conventional treatments.
  • This treatments results in excellent functional outcomes.
  • Transoral robotic surgery is also being investigated
Open partial laryngectomy (cricohyoidopexy [CHP] and cricohyoidoepiglottopexy [CHEP])
  • This procedure is a sound option for more advanced tumors (T3 or early T4).
  • This procedure involves resection of the vocal fold, thyroid cartilage, and paraglottic space.
  • Contraindications include cartilage invasion, bilateral vocal fold fixation, interarytenoid involvement, significant tongue base involvement, transglottic lesion, or poor performance status.
  • The surgeon must preserve at least 1 functional cricoarytenoid unit for speech and swallowing.
  • This procedure involves impaction of the cricoid and hyoid bone for larynx reconstruction.
  • This procedure can be performed with (CHEP) or without (CHP) epiglottis preservation, depending on glottic or supraglottic involvement.
  • Cure and organ preservation rates are comparable with chemoradiation.
  • Decreased voice quality may result.
  • Adequate swallowing can be achieved with rehabilitation.
  • This is a salvage option following radiotherapy.

Preoperative Details

When a patient is considering surgery, ascertaining that medical care is optimized is essential. Nutrition should be stable. Pain must be controlled. A trip to the dentist is essential to be sure the dentition is free of active infection. Tobacco and alcohol are best avoided.

Patients with severe lung disease may not be candidates for larynx-sparing surgery. Similarly, patients with compromised heart and renal disease may not be candidates for chemotherapy.

The patient who has had prior irradiation to the head and neck area represents a special problem. Re-irradiation can be undertaken, sometimes with good results, but the risk of severe complications is increased.

Intraoperative Details

This chapter does not allow for an in-depth discussion of operative technique. The author would refer the interested reader to an atlas where the various techniques are depicted. 

Under most circumstances, endoscopic resections are carried out with a tracheotomy. Many patients can be discharged on the day of the procedure. Extensive supraglottic resections do cause dysphagia and potentiate aspiration, so these patients require hospitalization and swallowing therapy.

Open partial laryngeal resections are almost always accompanied by a temporary tracheotomy. Most patients are decannulated prior to or soon after discharge. The vocal result is generally reflective of the extent of surgery. Most patients have a dysphonic but serviceable voice. 

Following total laryngectomy, the authors recommend immediate insertion of a tracheoesophageal stent to accommodate a voice prosthesis. These patients can be speaking about 3 weeks after surgery.

Postoperative Details

Recovery from laryngeal surgery is reflective of the structures removed, the extent of the resection, and the patient's underlying cardio-pulmonary health. The patient who undergoes resection for a small tumor can be predicted to have excellent functional recovery with good voice. Treatment of advanced  cancer always results in compromise of some quality of life and functional capabilities.

Follow-up

Follow-up care is necessary because second primary cancers, recurrences, and late metastases are all strong possibilities. In the course of a lifetime, one third of patients with head and neck cancer may develop another cancer.

The assistance of speech therapists, occupational therapists, and physical therapists with experience in swallowing or secretion control should also be considered.

Complications

The complications and consequences of surgery, radiation therapy, and chemotherapy are well known. However, in the larynx, unique or at least unusual complications must be considered. These are listed as follows:

  • Loss of upper body strength after laryngectomy
  • Psychosocial trauma from surgery and/or radiation therapy4
  • Limited mobility of the neck
  • Daily stoma care
  • Vocal cord–powered voice loss in some procedures
  • Aspiration pneumonia, in some procedures
  • Radiation-induced neoplasms of the neck
  • Osteoradionecrosis
  • Chondroradionecrosis
  • Chronic pain
  • Breathing difficulties
  • Stoma infections
  • Potential stoma malignancies

More on Malignant Tumors of the Larynx

Overview: Malignant Tumors of the Larynx
Workup: Malignant Tumors of the Larynx
Treatment: Malignant Tumors of the Larynx
Follow-up: Malignant Tumors of the Larynx
Multimedia: Malignant Tumors of the Larynx
References

References

  1. American Joint Comittee on Cancer - Head and Neck cancer staging 2007. Available at http://www.cancerstaging.org/. Accessed August 2008.

  2. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. Jun 13 1991;324(24):1685-90. [Medline].

  3. NCCN Practice Guidelines in Oncology - v.2.2008 - Head and Neck Cancers. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Accessed 7/1/07.

  4. De Santis M, Tripodi D. [The laryngectomized patient as a psychologically maladjusted person]. Valsalva. Jun 1968;44(3):138-45. [Medline].

  5. Ah-See K. The evidence for different management strategies for laryngeal cancer: summaries of systematic reviews commissioned for an educational meeting. Clin Otolaryngol. Apr 2008;33(2):90-3. [Medline].

  6. American Cancer Society. Cancer Facts and Figures 2005. [Full Text].

  7. Audet N, Beasley NJ, MacMillan C, et al. Lymphatic vessel density, nodal metastases, and prognosis in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. Dec 2005;131(12):1065-70. [Medline].

  8. Blair A, Kazerouni N. Reactive chemicals and cancer. Cancer Causes Control. May 1997;8(3):473-90. [Medline].

  9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. Feb 9 2006;354(6):567-78. [Medline].

  10. Cancer of the larynx. In: Myers EN, Suen JY, Myers JN, Hanna EYN. Cancer of the Head and Neck. 4th. Philadelphia: Saunders; 2003:333-378.

  11. Folz BJ, Silver CE, Rinaldo A, et al. An outline of the history of head and neck oncology. Oral Oncol. Jan 2008;44(1):2-9. [Medline].

  12. Garas J, McGuirt WF Sr. Squamous cell carcinoma of the subglottis. Am J Otolaryngol. Jan-Feb 2006;27(1):1-4. [Medline].

  13. Higgins KM, Wang JR. State of head and neck surgical oncology research--a review and critical appraisal of landmark studies. Head Neck. Dec 2008;30(12):1636-42. [Medline].

  14. Holsinger FC. Swing of the pendulum: optimizing functional outcomes in larynx cancer. Curr Oncol Rep. Mar 2008;10(2):170-5. [Medline].

  15. Kapil U, Singh P, Bahadur S, et al. Assessment of risk factors in laryngeal cancer in India: a case-control study. Asian Pac J Cancer Prev. Apr-Jun 2005;6(2):202-7. [Medline].

  16. Koufman JA, Burke AJ. The etiology and pathogenesis of laryngeal carcinoma. Otolaryngol Clin North Am. Feb 1997;30(1):1-19. [Medline].

  17. Lohynska R, Slavicek A, Bahanan A, et al. Predictors of local failure in early laryngeal cancer. Neoplasma. 2005;52(6):483-8. [Medline].

  18. Marks JE, Breaux S, Smith PG, et al. The need for elective irradiation of occult lymphatic metastases from cancers of the larynx and pyriform sinus. Head Neck Surg. Sep-Oct 1985;8(1):3-8. [Medline].

  19. McCaffrey TV, Witte M, Ferguson MT. Verrucous carcinoma of the larynx. Ann Otol Rhinol Laryngol. May 1998;107(5 Pt 1):391-5. [Medline].

  20. Mozolewski E, Maj P, Tarnowska C. [The choice of transplantation in reconstructive surgery of the larynx after partial laryngectomy]. Otolaryngol Pol. 1997;51(3):286-96. [Medline].

  21. Myers EN, Suen JY. Cancer of the larynx. Cancer of the Head and Neck. 1996;403-406.

  22. National Cancer Institute. Laryngeal Cancer (PDQ): Treatment.

  23. Nogueira CP, Dolan RW, Gooey J, et al. Inactivation of p53 and amplification of cyclin D1 correlate with clinical outcome in head and neck cancer. Laryngoscope. Mar 1998;108(3):345-50. [Medline].

  24. Oztürk O, Sari M, Inanli S, et al. Basaloid squamous cell carcinoma of the larynx: a case report. Kulak Burun Bogaz Ihtis Derg. 2005;15(5-6):125-9. [Medline].

  25. Rodriguez CP, Adelstein DJ, Rybicki LA, et al. Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck. Dec 2008;30(12):1535-42. [Medline].

  26. Santos AB, Cernea CR, Inoue M, et al. Selective neck dissection for node-positive necks in patients with head and neck squamous cell carcinoma: a word of caution. Arch Otolaryngol Head Neck Surg. Jan 2006;132(1):79-81. [Medline].

  27. Sathiakumar N, Delzell E, Amoateng-Adjepong Y, et al. Epidemiologic evidence on the relationship between mists containing sulfuric acid and respiratory tract cancer. Crit Rev Toxicol. May 1997;27(3):233-51. [Medline].

  28. Scheifele C, Reichart PA, Hippler-Benscheidt M, et al. Incidence of oral, pharyngeal, and laryngeal squamous cell carcinomas among 1515 patients after liver transplantation. Oral Oncol. Aug 2005;41(7):670-6. [Medline].

  29. Shah JP, Karnell LH, Hoffman HT, et al. Patterns of care for cancer of the larynx in the United States. Arch Otolaryngol Head Neck Surg. May 1997;123(5):475-83. [Medline].

  30. Silverberg E. Cancer statistics, 1985. CA Cancer J Clin. Jan-Feb 1985;35(1):19-35. [Medline].

  31. Succo G, Bramardi F, Airoldi M, et al. Quality of life after treatment in patients with laryngeal carcinoma [in Italian]. Acta Otorhinolaryngol Ital. 1997/02;17(1):32-44.

  32. Surveillance, Epidemiology and End Results (SEER) Program. NCI; 2008. [Full Text].

  33. Uneri C, Sari M, Baglam T, et al. Effects of vitamin E on cigarette smoke induced oxidative damage in larynx and lung. Laryngoscope. Jan 2006;116(1):97-100. [Medline].

  34. Vermund H, Krajci P, Eide TJ, et al. Histopathological grading of laryngectomy specimens. APMIS. Jul-Aug 2005;113(7-8):473-88. [Medline].

  35. Vermund H, Krajci P, Eide TJ, et al. Laryngectomy whole organ serial sections--histological parameters correlated with recurrence rate. Acta Oncol. 2004;43(1):98-107. [Medline].

  36. Wenig BM. Atlas of Head and Neck Pathology. Philadelphia, Pa: WB Saunders; 1993:255.

  37. Zeitels SM, Vaughan CW, Domanowski GF. Endoscopic management of early supraglottic cancer. Ann Otol Rhinol Laryngol. Dec 1990;99(12):951-6. [Medline].

  38. Zeitels SM, Vaughan CW, Domanowski GF, et al. Laser epiglottectomy: endoscopic technique and indications. Otolaryngol Head Neck Surg. Sep 1990;103(3):337-43. [Medline].

Further Reading

Keywords

malignant tumors of the larynx, laryngeal cancer, cancer of the larynx, neck metastases, lymph node metastases, subglottic cancer, glottic cancer, supraglottic cancer, neck cancer, laryngectomy, neck tumor, subglottic tumor, glottic tumor, supraglottic tumor, transglottic tumor, tumors of the transglottic larynx, vocal cord cancer, vocal cord tumor, laryngeal malignancy, squamous cell carcinoma of the larynx,

Contributor Information and Disclosures

Author

Jonas T Johnson, MD, FACS, Chairman, Department of Otolaryngology, The Eugene N Myers, MD, Professor and Chairman of Otolaryngology, Professor, Department of Radiation Oncology, University of Pittsburgh School of Medicine; Professor, Department of Oral Maxillofacial Surgery, University of Pittsburgh School of Dental Medicine
Jonas T Johnson, MD, FACS is a member of the following medical societies: Allegheny County Medical Society, American Academy of Otolaryngology-Head and Neck Surgery, American Association for Cancer Research, American Bronchoesophagological Association, American College of Surgeons, American Head and Neck Society, American Laryngological Association, American Laryngological Rhinological and Otological Society, American Medical Association, American Radium Society, American Rhinologic Society, American Society of Clinical Oncology, Pennsylvania Medical Society, and Society of University Otolaryngologists-Head and Neck Surgeons
Disclosure: Nothing to disclose.

Coauthor(s)

Apostolos Christopoulos, MD, MSc, FRCSC, Fellow in Head and Neck Oncologic Surgery, Department of Otolaryngology, University of Pittsburgh
Disclosure: Nothing to disclose.

Emiro E Caicedo-Granados, MD, Fellow in Head and Neck Oncology/Anterior Endoscopic Skull Base Surgery, Department of Otolaryngology, University of Pittsburgh
Emiro E Caicedo-Granados, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery
Disclosure: Nothing to disclose.

Medical Editor

Jack A Coleman, MD, Consulting Staff, Franklin Surgical Associates
Jack A Coleman, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Sleep Medicine, American Bronchoesophagological Association, American College of Surgeons, American Laryngological Rhinological and Otological Society, American Society for Laser Medicine and Surgery, and Association of Military Surgeons of the US
Disclosure: Influent  None Review panel membership; accarent, inc Honoraria Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Karen Hall Calhoun, MD, William E Davis Professor and Chair, Department of Otolaryngology-Head and Neck Surgery, University of Missouri
Karen Hall Calhoun, MD is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngic Allergy, American Academy of Otolaryngology-Head and Neck Surgery, American College of Surgeons, American Head and Neck Society, American Medical Association, American Rhinologic Society, Association for Research in Otolaryngology, Society of University Otolaryngologists-Head and Neck Surgeons, Southern Medical Association, Texas Medical Association, and Texas Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: Covidien Corp Consulting fee Consulting; US Tobacco Corporation unstricted gift unknown

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.